Dana-Farber Cancer Institute

The Investment Committee is chaired by Chris Hadley, a managing director at Berkshire Partners with deep private equity experience. He is joined on the Board of Trustees by Josh Bekenstein, co-chairman of Bain Capital, and Richard Lubin, co-founder of Berkshire Partners. This governance structure places investment oversight in the hands of Boston-based private equity principals rather than traditional institutional asset managers.

Unlike a university endowment that supports broad academic operations, Dana-Farber's endowment serves a single-mission institution: cancer research and clinical care. The portfolio must fund fixed-cost research infrastructure — lab space, investigator salaries, clinical trial operations — while also supporting brick-and-mortar expansion like the future cancer hospital at One Joslin Place. This creates a sharper liquidity-need profile than a diversified university fund.

Investment allocation specifics are not publicly disclosed, so whether the endowment takes direct life-science positions is not publicly known. Its trustee composition — Boston private equity investors — suggests familiarity with direct and co-investment structures, but no public record confirms direct biotech company positions within the endowment portfolio itself. The institute's primary exposure to drug development comes through its operating side, where it conducts clinical trials for pharmaceutical partners.

Dana-Farber is the principal teaching affiliate for oncology at Harvard Medical School. This relationship means Dana-Farber faculty hold Harvard Medical School appointments and the institute trains Harvard medical students and fellows in cancer specialization. The affiliation also ties Dana-Farber into the broader Harvard hospital ecosystem, including Brigham and Women's Hospital and Boston Children's Hospital, both clinical partners for inpatient care.

Two affiliated foundations channel philanthropic giving: Friends of Dana-Farber Cancer Institute and The Jimmy Fund. The Jimmy Fund, established in 1948, is the institute's primary fundraising arm and has deep ties to Boston civic life, including longstanding sponsorship from the Boston Red Sox. These foundations operate as separate 501(c)(3) vehicles but exist solely to support Dana-Farber's research and clinical mission.

The Dana-Farber/Harvard Cancer Center (DF/HCC) is a National Cancer Institute-designated comprehensive cancer center that pools research across Harvard-affiliated hospitals including Dana-Farber, Massachusetts General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital. This consortium approach allows shared clinical trial infrastructure and cross-institutional investigator teams, funded in part by NCI grants rather than endowment draw.